The TASCC study is a longitudinal assessment study. In it, we examine treatment adherence, concomitant patient and family behavioral functioning and QOL in adolescents (ages 13-17) with IBD. The primary aims of this study are to identify behavioral factors related to nonadherence in this population, and to examine patterns of adherence and related factors over time. The study’s findings will inform continued intervention research.
This study was supported by Prometheus Laboratories and Procter & Gamble Pharmaceuticals.